CN117677627A - 分拣蛋白活性调节剂 - Google Patents

分拣蛋白活性调节剂 Download PDF

Info

Publication number
CN117677627A
CN117677627A CN202280030307.9A CN202280030307A CN117677627A CN 117677627 A CN117677627 A CN 117677627A CN 202280030307 A CN202280030307 A CN 202280030307A CN 117677627 A CN117677627 A CN 117677627A
Authority
CN
China
Prior art keywords
acid
acetamido
alkyl
ser
propionylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030307.9A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·布莱恩·黎托
曼努埃尔·哈维尔·凯斯-托马斯
麦德斯·富格桑·克约尔比
安德斯·纽易尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innocence Ltd
Original Assignee
Innocence Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innocence Ltd filed Critical Innocence Ltd
Publication of CN117677627A publication Critical patent/CN117677627A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Secondary Cells (AREA)
  • Sawing (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280030307.9A 2021-04-23 2022-04-22 分拣蛋白活性调节剂 Pending CN117677627A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21170274.1A EP4079748A1 (en) 2021-04-23 2021-04-23 Modulators of sortilin activity
EP21170274.1 2021-04-23
PCT/EP2022/060742 WO2022223805A1 (en) 2021-04-23 2022-04-22 Modulators of sortilin activity

Publications (1)

Publication Number Publication Date
CN117677627A true CN117677627A (zh) 2024-03-08

Family

ID=75674611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280030307.9A Pending CN117677627A (zh) 2021-04-23 2022-04-22 分拣蛋白活性调节剂

Country Status (8)

Country Link
US (1) US20240217922A1 (cg-RX-API-DMAC7.html)
EP (2) EP4079748A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517678A (cg-RX-API-DMAC7.html)
KR (1) KR20240000510A (cg-RX-API-DMAC7.html)
CN (1) CN117677627A (cg-RX-API-DMAC7.html)
AU (1) AU2022260554A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215848A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022223805A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143648A (zh) * 2022-12-05 2023-05-23 河北远大九孚生物科技有限公司 一种n-乙酰-l-苯丙氨酸的合成方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471047A1 (en) * 2023-05-31 2024-12-04 Insusense ApS Modulators of sortilin activity
EP4361165A1 (en) * 2022-10-24 2024-05-01 Insusense ApS Modulators of sortilin activity
EP4428124A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4428121A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors
TW202600557A (zh) * 2024-02-20 2026-01-01 日商大塚製藥股份有限公司 作為sort1抑制劑之哌啶-及嗎啉-羧酸鹽化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183551A (ja) * 1986-10-31 1988-07-28 ファイザー・インコーポレーテッド ノルスタチンおよびノルシクロスタチンポリペプチド
DE3842067A1 (de) * 1988-12-14 1990-06-21 Hoechst Ag Enzym-hemmende aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
JPH05345754A (ja) * 1992-06-15 1993-12-27 Suntory Ltd ジペプチド誘導体およびそれを有効成分とする骨疾患の予防または治療剤
DE19546532C2 (de) * 1995-12-13 2000-04-20 Degussa Verfahren zur Gewinnung von optisch aktiven L-alpha-Aminocarbonsäuren aus entsprechenden racemischen D,L-alpha-Aminocarbonsäuren
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2006050861A2 (en) * 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
JP2009503027A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病iiの治療のための置換エタン−1,2−ジアミン
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
GB201011411D0 (en) * 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
US9682967B2 (en) * 2013-01-28 2017-06-20 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
WO2015131100A1 (en) 2014-02-28 2015-09-03 The Scripps Research Institute Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143648A (zh) * 2022-12-05 2023-05-23 河北远大九孚生物科技有限公司 一种n-乙酰-l-苯丙氨酸的合成方法

Also Published As

Publication number Publication date
US20240217922A1 (en) 2024-07-04
CA3215848A1 (en) 2022-10-27
AU2022260554A1 (en) 2023-11-02
WO2022223805A1 (en) 2022-10-27
KR20240000510A (ko) 2024-01-02
AU2022260554A9 (en) 2023-11-16
EP4079748A1 (en) 2022-10-26
EP4326742A1 (en) 2024-02-28
JP2024517678A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
US20240217922A1 (en) Modulators of sortilin activity
CN117642416A (zh) 分拣蛋白活性调节剂
AU2001264977B2 (en) Melanocortin receptor agonists
TW577879B (en) Novel compounds exhibiting growth hormone secretagogue activity, pharmaceutical composition containing the same and their uses
EP3981394A1 (en) A sortilin antagonist for use in the prevention or treatment of hearing loss.
CN114728170B (zh) 对核受体具有活性的化合物
CN103896946A (zh) 用于预防及治疗多种自身免疫疾病的新化合物
JP7645434B2 (ja) インターロイキン-1βを捕捉するための環状ペプチド
KR20190031518A (ko) 치환된 디아자헤테로비시클릭 화합물 및 그의 용도
KR20230135085A (ko) 소르틸린 활성 조절제로서의 피리딘 유도체
RU2851145C1 (ru) Циклические агонисты апелинового рецептора
RU2849956C1 (ru) Линейные агонисты апелинового рецептора
EP4428124A1 (en) Modulators of sortilin activity
RU2838225C1 (ru) Агонисты рецепторов glp
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
CA3080202A1 (en) Oxadiazoles and thiadiazoles as tgf-beta inhibitors
KR20190138824A (ko) 치환된 n-아릴에틸-2-아릴퀴놀린-4-카르복스아미드 및 그의 용도
JP2026509274A (ja) ソルチリン活性の修飾剤
JP2026067760A (ja) C3a受容体拮抗化合物及びその利用
KR20230086683A (ko) 사이클릭 아펠린 수용체 효능제
CN117586230A (zh) 降解ebna1的protac化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Denmark

Address after: Tanba Goro haro

Applicant after: Wisper Biological Applications Co.,Ltd.

Address before: Tanba Goro haro

Applicant before: Innocence Ltd.

Country or region before: Denmark

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Denmark

Address after: Room 4, 10 Hauser Street, Copenhagen, Denmark

Applicant after: Wisper Biological Applications Co.,Ltd.

Address before: Tanba Goro haro

Applicant before: Wisper Biological Applications Co.,Ltd.

Country or region before: Denmark